UFA
BBIO icon

US Financial Advisors’s BridgeBio Pharma BBIO Stock Holding History

US Financial Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,000
Closed -$370K – 79
2021
Q1 		$370K Hold
6,000
– – 0.1% 99
2020
Q4 		$427K Buy
+6,000
New +$289K 0.13% 74

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

US Financial Advisors's BBIO Position: Q2 2021 in Review

US Financial Advisors sold out of BridgeBio Pharma (BBIO) in Q2 2021, closing a stake of 6,000 shares — an estimated $370K sold.

US Financial Advisors first reported a position in BBIO in Q4 2020 and held it in 2 quarters. The position peaked at $427K in Q4 2020. 200 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

  • US Financial Advisors reported no remaining BridgeBio Pharma position as of Q2 2021 after selling out during the quarter.
  • US Financial Advisors sold 6,000 BridgeBio Pharma shares in Q2 2021, an estimated $370K.
  • US Financial Advisors first reported a position in BridgeBio Pharma in Q4 2020 and held it in 2 quarters.
  • US Financial Advisors's BridgeBio Pharma position peaked at $427K in Q4 2020.
  • 200 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on US Financial Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.